Edition:
United States

Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

1.24USD
26 May 2017
Change (% chg)

$-0.01 (-0.80%)
Prev Close
$1.25
Open
$1.23
Day's High
$1.27
Day's Low
$1.23
Volume
20,289
Avg. Vol
96,843
52-wk High
$3.09
52-wk Low
$1.11

ACST.O

Chart for ACST.O

About

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $24.72
Shares Outstanding(Mil.): 14.71
Dividend: --
Yield (%): --

Financials

  ACST.O Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -0.92 -- --
ROI: -39.89 -7.17 -5.42
ROE: -40.16 -6.63 -4.68

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia

Apr 12 2017

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

* Acasti Pharma provides update on Capre phase 3 development program

Mar 30 2017

BRIEF-Acasti Pharma announces pricing for its public offering of units

* Acasti Pharma announces pricing for its public offering of units

Feb 10 2017

BRIEF-Acasti Pharma Q3 loss C$0.22/shr

* Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016

Jan 12 2017

BRIEF-Acasti Pharma appoints Linda O'keefe as chief financial officer

* Acasti Pharma appoints Linda O'keefe as chief financial officer

Nov 28 2016

More From Around the Web

Earnings vs. Estimates